Flare phenomenon in advanced colorectal cancer: Cessation of bevacizumab after predefined cycles of therapy may not affect outcome İleri evre kolorektal kanserli hastalarda alevlenme fenomeni: Önceden belirlenmiş sayida verilen bevasizumabin kesilmesi sağkalimi olumsuz etkilemeyebilir

Creative Commons License

Besen A. A., Kose F., Sumbul A. T., Ozdemir N., Ozyilkan O., ZENGİN N., ...Daha Fazla

UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi, cilt.27, sa.1, ss.53-59, 2017 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 27 Sayı: 1
  • Basım Tarihi: 2017
  • Doi Numarası: 10.4999/uhod.171617
  • Dergi Adı: UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.53-59
  • Anahtar Kelimeler: Flare phenomenon, Colorectal cancer, Bevacizumab cessation, Chemotherapy, Rebound progression, TUMOR-GROWTH, BEVACIZUMAB, FLUOROURACIL, LEUCOVORIN, OXALIPLATIN, COMBINATION, PROGRESSION, IRINOTECAN
  • Lokman Hekim Üniversitesi Adresli: Hayır

Özet

© 2017, UHOD - Uluslararasi Hematoloji Onkoloji Dergisi. All rights reserved.Limited number of experimental and clinical studies showed rapid tumor regrowth after bevacizumab cessation in advanced colorectal cancer. We retrospectively evaluated rapid regrowth phenomenon in 105 patients those who were treated with the predefined number of chemotherapy cycles and grouped according to whether the chemotherapy regimen in the first line setting included bevacizumab (CT-Bev arm) or not (CT arm). Median age was 55 years old. Median overall and progression free survival times were 27 and 11 months, respectively. Rapid progression rates were 42% and 40% in CT arm and CT-Bev arm without no statistically significant differ- ence (p= 0.84). In CT arm, significantly more patients with stable disease (SD) progressed rapidly compared to patients with complete (CR) or partial response (PR) (53% vs. 27%, p= 0.04). This result was also similar in CT-Bev arm (48% vs. 30%, p= 0.27) but could not reach to the significant p-value. Overall survival 2, the time from the end of last dose of chemotherapy +/- bevacizumab to death, was significantly shorter in both CT and CT-Bev arms for patients who showed SD compared to CR or PR (15 vs 38 months) (p< 0.001).Current study supports that withdrawal of bevacizumab after predefined treatment cycles may not have any adverse effect on patients’ outcome of advanced CRC. This result is particularly acceptable for the patients who show CR or PR to the treatment.